Mr. Bryan Baldasare - 23 Dec 2023 Form 4 Insider Report for InMed Pharmaceuticals Inc. (INM)

Reporting relationship: Director
Issuer ticker: INM
Reported as of: 23 Dec 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Dec 2023, 13:05:14 UTC
Prior SEC filing: 19 Dec 2022
Next SEC filing: 23 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Eric A Adams, attorney-in-fact for Mr. Bryan Baldasare

Key filing fact

Mr. Bryan Baldasare filed Form 4 for InMed Pharmaceuticals Inc. (INM) on 26 Dec 2023.

Key facts

This page summarizes Mr. Bryan Baldasare's Form 4 filing for InMed Pharmaceuticals Inc. (INM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Dec 2023, 13:05.

Change

Previous filing in this sequence was filed on 19 Dec 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INM transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +7,100
Change %: +507%
Price: $0.000000
Shares after: 8,500
Date: 23 Dec 2023
Ownership: Direct
Underlying class: Common shares
Underlying amount: 7,100
Exercise price: $0.3700
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options were granted on 12/23/2023 and will vest 100% on the one-year anniversary of the grant date (December 23, 2024) or immediately prior to the next Annual General Meeting, whichever is sooner.